Searched for
AUROBINDO AND CIPLA
Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- US foreign aid ban hits HIV-related local drug stocksLaurus Labs slumped 11.6%, Aurobindo declined 2%, Cipla fell 1.1% and Strides dropped 5%. Other pharma shares also declined with 19 out of ...
- Lupin, Glenmark Pharma, 7 BSE Healthcare stocks which hit 52-week high on WednesdayThe data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only ...
- Aurobindo, Cipla, Viatris in licensing pact with MPP to make ViiV's HIV preventive therapyThrough the MPP-ViiV Healthcare agreement, the three generic manufacturers will be able to develop, manufacture, and supply generic version...
- HSBC says US generic probe concern to weigh on sentiment for pharma cosShares of Sun Pharmaceutical will be closely watched due to its material exposure to doxycycline development amid report that doxycycline-a...
- Pharma headwinds here to stay, tread with cautionSeven pharma cos' managements say pricing pressure and tightening regulatory noose worrisome in near term, but long-term outlook's healthy.
- Cipla, Aurobindo, Emcure to supply HIV drugs for UN-backed programmeAurobindo Pharma Chief Executive Officer said the new licence would help ensure the timely introduction of generic ATV in developing countr...
- Go short on Aurobindo Pharma with a stop at 116.50: Mitesh Thacker, miteshthacker.comThat is the one stock which can be shorted with a stop at about 116.50.
- Aurobindo Pharma's longer term trend turned down: Deepak MohoniAurobindo falls in the vulnerable category of pharma stocks.
- Like Cipla in pharma space: Vivek Mahajan, Aditya Birla MoneyIt will make more sense to stick with the large cap companies in the pharma space.
- Buy Aurobindo Pharma for Rs 1450-1500 target in 3 weeks: Devang VisariaWith a three weeks' time horizon, we are looking for targets closer to Rs 1,450-1,500 for Aurobindo Pharma.
- Cipla and Ranbaxy are showing strength: EdelweissJitendra Mehta, technical analyst, Edelweiss, in a chat with ET Now talks about Strides Arcolab or an Aurobindo Pharma.
- If you are patient, Cipla is a good buy: Devang VisariaDevang Visaria, chief strategist, Devangvisraia, in a chat with ET Now talks about the pharma stocks.
- Zee Entertainment looks good but volumes are very low: Sandeep WagleET Now caught up with Sandeep Wagle,Founder & MD, APTART Technical Advisory Services, aptartindia.com to know his views on various stocks.
- Indian firms get lion's share in US anti-AIDS fundingAurobindo Pharma, Cipla and Ranbaxy, have received a lion's share of over 85 per cent in the US government's latest fiscal funding for AIDS...
Load More
